NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated … Read more
NextCell Pharma AB (NXTCL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of August 2025: -0.162x
Based on the latest financial reports, NextCell Pharma AB (NXTCL) has a cash flow conversion efficiency ratio of -0.162x as of August 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.77 Million) by net assets (Skr66.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NextCell Pharma AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how NextCell Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NextCell Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NextCell Pharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
J.S.P. Property Public Company Limited
BK:JSP
|
0.025x |
|
Airthings ASA
PINK:ARTGF
|
-0.038x |
|
Eureka Design Public Company Limited
BK:UREKA
|
0.002x |
|
Avonmore Capital & Management Services Limited
NSE:AVONMORE
|
0.003x |
|
Bionano Genomics Inc
NASDAQ:BNGO
|
-0.119x |
|
Dongsung Pharm
KO:002210
|
0.104x |
|
Chonburi Concrete Product Public Company Limited
BK:CCP
|
0.074x |
|
Cadence Opportunities Fund Ltd
AU:CDO
|
0.000x |
Annual Cash Flow Conversion Efficiency for NextCell Pharma AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of NextCell Pharma AB from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | Skr66.39 Million | Skr-38.86 Million | -0.585x | -4.75% |
| 2024-08-31 | Skr67.60 Million | Skr-37.78 Million | -0.559x | +3.43% |
| 2023-08-31 | Skr75.73 Million | Skr-43.83 Million | -0.579x | -100.73% |
| 2022-08-31 | Skr115.54 Million | Skr-33.31 Million | -0.288x | -69.19% |
| 2021-08-31 | Skr150.09 Million | Skr-25.58 Million | -0.170x | +76.44% |
| 2020-08-31 | Skr26.22 Million | Skr-18.96 Million | -0.723x | +24.99% |
| 2019-08-31 | Skr22.96 Million | Skr-22.13 Million | -0.964x | +64.13% |
| 2018-08-31 | Skr5.04 Million | Skr-13.55 Million | -2.688x | -246.01% |
| 2017-08-31 | Skr19.07 Million | Skr-14.82 Million | -0.777x | +52.74% |
| 2016-08-31 | Skr6.76 Million | Skr-11.12 Million | -1.644x | -106.93% |
| 2015-08-31 | Skr9.77 Million | Skr-7.76 Million | -0.794x | -- |